Myocardial technetium-99m-tetrofosmin single-photon emission computed tomography compared with 18F-fluorodeoxyglucose imaging to assess myocardial viability

Arend F L Schinkel; Jeroen J Bax; Elena Biagini; Abdou Elhendy; Ron T van Domburg; Roelf Valkema; Vittoria Rizzello; Olaf Schouten; Maarten Simoons; Don Poldermans

doi:10.1016/j.amjcard.2005.01.050

Myocardial technetium-99m-tetrofosmin single-photon emission computed tomography compared with 18F-fluorodeoxyglucose imaging to assess myocardial viability

Am J Cardiol. 2005 May 15;95(10):1223-5. doi: 10.1016/j.amjcard.2005.01.050.

Authors

Arend F L Schinkel¹, Jeroen J Bax, Elena Biagini, Abdou Elhendy, Ron T van Domburg, Roelf Valkema, Vittoria Rizzello, Olaf Schouten, Maarten Simoons, Don Poldermans

Affiliation

¹ Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands.

PMID: 15877995
DOI: 10.1016/j.amjcard.2005.01.050

Abstract

Technetium-99m-tetrofosmin single-photon emission computed tomography at rest is practical for routine assessment of viability in patients with ischemic cardiomyopathy. However, underestimation of viability may occur compared with 18F-fluorodeoxyglucose single-photon emission computed tomography, especially in the inferoposterior and septal regions.

Publication types

Comparative Study
Evaluation Study

MeSH terms

Coronary Artery Disease / diagnostic imaging*
Coronary Artery Disease / pathology
Female
Fluorodeoxyglucose F18*
Humans
Male
Middle Aged
Organophosphorus Compounds*
Organotechnetium Compounds*
Predictive Value of Tests
Radiopharmaceuticals*
Tomography, Emission-Computed, Single-Photon / methods*
Ventricular Dysfunction, Left / diagnostic imaging*
Ventricular Dysfunction, Left / pathology

Substances

Organophosphorus Compounds
Organotechnetium Compounds
Radiopharmaceuticals
Fluorodeoxyglucose F18
technetium tc-99m tetrofosmin